Prospective interventional study to evaluate the efficacy and safety of liposomal amphotericin B as prophylaxis of fungal infections in high-risk liver transplant recipients

被引:38
作者
Castroagudín, JF
Pontón, C
Bustamante, M
Otero, E
Martínez, J
Tomé, S
Conde, R
Segade, FR
Delgado, M
Brage, A
Galbán, C
Varo, E
机构
[1] Univ Hosp, Liver Transplantat Unit, Santiago De Compostela, Spain
[2] Univ Hosp, Crit Care Unit, Santiago De Compostela, Spain
关键词
D O I
10.1016/j.transproceed.2005.10.043
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction. Invasive fungal infections are a life-threatening complication in transplant recipients. The prevalence of fungal infection after orthotopic liver transplantation (OLT) is 5% to 42%. The most common isolated pathogens are Candida and Aspergillus species. High-risk liver transplant recipients are more susceptible to the development of invasive fungal infections, with prevalence > 40% and mortality rates of 78% to 100%. The strategy for fungal prophylaxis in this population has not been defined. Patients and methods. Among 100 consecutive OLT followed for 28 months, 21 recipients (15 men, overall mean age of 48.5 years, range 23-65 years) were considered to be high risk for the development of fungal infections when they presented at least one of the following criteria: acute liver failure, assisted ventilation > 7 days, retransplantation, relaparotomy, antibiotic therapy > 14 days, transfusion requirements > 20 red blood cells units, and/or biliary leakage. This group received intravenous liposomal amphotericin B (1 mg/kg/d for 7-10 days). Results. One-year survival in the high-risk group was 80%. Prevalence of invasive fungal infection was 9.5%. No Candida infection was observed. Two patients developed Aspergillus infection: an abdominal aspergillosis treated with percutaneous drainage and liposomal amphotericin B (5 mg/kg/d) showed a favorable clinical outcome. The other patient who developed brain aspergillosis died 25 days after OLT. Adverse events related to the drug were hypokalemia (n = 2), back pain (n = 3), and renal dysfunction (n = 2). None of these events required withdrawal of the prophylaxis regimen. Conclusion. In our series, prophylaxis with liposomal amphotericin B in high-risk liver graft recipients showed a low rate of severe fungal infections. More studies are needed in order to determine the highest risk population and the best drug dosage.
引用
收藏
页码:3965 / 3967
页数:3
相关论文
共 8 条
  • [1] AmBisome (Liposomal amphotericin B): A comparative review
    Boswell, GW
    Buell, D
    Bekersky, I
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 38 (07) : 583 - 592
  • [2] Is liposomal amphotericin B (Ambisome) an effective prophylaxis of mycotic infections after liver transplantation?
    Braun, F
    Rüchel, R
    Lorf, T
    Canelo, R
    Müller, A
    Sattler, B
    Ringe, B
    [J]. TRANSPLANTATION PROCEEDINGS, 1998, 30 (04) : 1481 - 1483
  • [3] RISK-FACTORS FOR INVASIVE FUNGAL-INFECTIONS COMPLICATING ORTHOTOPIC LIVER-TRANSPLANTATION
    COLLINS, LA
    SAMORE, MH
    ROBERTS, MS
    LUZZATI, R
    JENKINS, RL
    LEWIS, WD
    KARCHMER, AW
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1994, 170 (03) : 644 - 652
  • [4] FUNGAL-INFECTIONS IN SOLID-ORGAN TRANSPLANTATION
    PAYA, CV
    [J]. CLINICAL INFECTIOUS DISEASES, 1993, 16 (05) : 677 - 688
  • [5] Invasive aspergillosis in liver transplant recipients in the 1990s
    Singh, N
    Arnow, PM
    Bonham, A
    Dominguez, E
    Paterson, DL
    Pankey, GA
    Wagener, MM
    Yu, VL
    [J]. TRANSPLANTATION, 1997, 64 (05) : 716 - 720
  • [6] Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy
    Singh, N
    Paterson, DL
    Gayowski, T
    Wagener, MM
    Marino, IR
    [J]. TRANSPLANTATION, 2001, 71 (07) : 910 - 913
  • [7] Targeted prophylaxis with amphotericin B lipid complex in liver transplantation
    Singhal, S
    Ellis, RW
    Jones, SG
    Miller, SJ
    Fisher, NC
    Hastings, JGM
    Mutimer, DJ
    [J]. LIVER TRANSPLANTATION, 2000, 6 (05) : 588 - 595
  • [8] LIPOSOMAL AMPHOTERICIN-B PREVENTS INVASIVE FUNGAL, INFECTIONS IN LIVER-TRANSPLANT RECIPIENTS - A RANDOMIZED, PLACEBO-CONTROLLED STUDY
    TOLLEMAR, J
    HOCKERSTEDT, K
    ERICZON, BG
    JALANKO, H
    RINGDEN, O
    [J]. TRANSPLANTATION, 1995, 59 (01) : 45 - 50